medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2015, Number 01

<< Back Next >>

Ginecol Obstet Mex 2015; 83 (01)

Comparison of results of two flexible ovarian hiperestimulation protocols with two different initial doses (150 vs ≥ 225)

Barros-Delgadillo JC, Ruiz-Balderrama CI, Ríos-Barba M

Language: Spanish
References: 21
Page: 1-15
PDF size: 494.22 Kb.


ABSTRACT

Background: With the use of new protocols Controlled ovarian hyperstimulation (COH) with lower doses of gonadotropins to the classics protocols and current trend of fewer embryos transferred, there is no agreement until today on the optimal dose start of a COH protocol.
Objective: Compare the results of two flexible protocols of HOC with different starting doses (150 vs 225 IU rFSH / hMG) plus a GnRH antagonist in cycles of IVF / ICSI.
Methods: Retrospective, descriptive study, we analyzed 231 cycles of IVF / ICSI being the primary variables: total FSH dose, dose increase, retrieved oocytes, embryos available for transfer and for cryopreservation.
Results: The total dose of FSH in group II was significantly higher versus group I (2096.0 vs 1447.9). The percentage of patients in whom the dose increased was higher in Group I vs Group II (26.4% vs 9.1%, p = 0.001). The number of retrieved oocytes was similar between the groups (10.5 vs 10.2, p = 0.76) as well as the number of embryos available the day of the transfer and the number of embryos that were vitrified 6.73 vs 6.08 (p = 0.97) and 1.5 and 1.3 (p=0.820) for Group I and II respectively. The clinical pregnancy rate was 39.3% (n = 91), and for groups I and II were 41.6 and 37.7% respectively.
Conclusions: No significant differences between two loading dose was found (150 vs ≥ 225) in most of the primary endpoint.


REFERENCES

  1. Macklon N, Stouffer R, Giudice L, Fauser B. The Science behind 25 Years of Ovarian Stimulation for in vitro fertilization. Endocrine Reviews 2006;27:170-207.

  2. Zarek S and Muasher S. Mild/minimal stimulation for in vitro fertilization: an old idea that needs to be revisited. Fertility and Sterility 2011;95:2449-2455.

  3. Nargund G, Fauser B, Macklon N , Ombelet W, et al. The ISMAAR proposal on terminology for ovarian stimulation for IVF. Human Reproduction 2007;22:2801-2804.

  4. Barros J, Fiszman R, Santibañez A, Sánchez V, y col. Resultados preliminares del estudio de eficacia de dos esquemas de hiperestimulación ovárica controlada con hormona folículo estimulante recombinante en ciclos de inseminación intrauterina. Ginecol Obstet Mex 2012;80:61-72

  5. Howles C, Saunders H, Alam V and Engrand P. Predictive factors and a corresponding treatment algorithm for controlled ovarian stimulation in patients treated with recombinant human follicle stimulating hormone (follitropin alfa) during assisted reproduction technology (ART) procedures. An analysis of 1378 patients. Current Medical Research and Opinion 2006;22:907-918.

  6. Loutradis D, Drakakis P, Vomvolaki E, Antsaklis A. Different ovarian stimulation protocols for women with diminished ovarian reserve. J Assist Reprod Genet 2007;24:597-611.

  7. Van Tilborg T, Eijkemans M, Laven J, Koks C, et al. The OPTIMIST study: optimization of cost effectiveness through individualized FSH stimulation dosages for IVF treatment. A randomized controlled trial. BMC Women’s Health 2012;12:3-7.

  8. Ehy N, Yeunget W, Ho P. Comparison of two dosages of recombinant human follicle-stimulating hormone in Chinese women undergoing controlled ovarian stimulation: Prospective randomized double-blind study. HKMJ 2000;6:368-374.

  9. Asian Puregon Study Group, Hoomans E and Mulder B. A Group-Comparative, Randomized, Double-Blind Comparison of the Efficacy and Efficiency of Two Fixed Daily Dose Regimens (100- and 200-IU) of Recombinant Follicle Stimulating Hormone (rFSH, Puregon®) in Asian Women Undergoing Ovarian Stimulation for IVF/ICSI. Journal of Assisted Reproduction and Genetics 2002;19:470-476.

  10. Out H, D Ishay, Ron-El R, Friedler S, et al. A randomized, double-blind clinical trial using fixed daily doses of 100 or 200 IU of recombinant FSH in ICSI cycles. Human Reproduction 2001;16:1104-1109.

  11. Hoomans E, Nyboe A, Loft A, Leerentveld A, et al. A prospective, randomized clinical trial comparing 150 IU recombinant follicle stimulating hormone (Puregon) and 225 IU highly purified urinary follicle stimulating hormone (Metrodin-HP) in a fixed-dose regimen in women undergoing ovarian stimulation. Human Reproduction 1999;14: 2442-2447.

  12. Sterrenburg M, Veltman-Verhulst S, Eijkemans M, Hughes E, et al. Clinical outcomes in relation to the daily dose of recombinant follicle- stimulating hormone for ovarian stimulation in in vitro fertilization in presumed normal responders younger than 39 years: a meta-analysis. Human Reproduction 2011;17:184-196.

  13. Yong P, Brett S, Baird D and Thong J. A prospective randomized clinical trial comparing 150 IU and 225 IU of recombinant follicle-stimulating hormone (Gonal-F*) in a fixed-dose regimen for controlled ovarian stimulation in in vitro fertilization treatment. Fertility and Sterility 2003;79:308-315.

  14. Barros J, Alvarado L, Gorbea V, Villalobos S, et al. Resultados perinatales de embarazos por fertilización in vitro con transferencia de embriones (FIVTE): un estudio de casos y controles. Ginecol Obstet Mex 2006;74:626-39.

  15. Parmegiani L, Cognigni G, Bernardi S, Trolio E, et al. Physiologic ICSI: hyaluronic acid (HA) favors selection of spermatozoa without DNA fragmentation and with normal nucleus, resulting in improvement of embryo quality. Fertil Steril 2010;93:598-604.

  16. Veeck L. An Atlas of Human Gametes and Concept uses, an illustrated Reference for Assisted Reproductive Technology. Parthenon Publishing Groups 1999;1113-1136.

  17. The Latin-American Puregon IVF Study Group. A double-blind clinical trial comparing a fixed daily dose of 150 and 250 IU of recombinant follicle-stimulating hormone in women undergoing in vitro fertilization. Fertil Steril 2001;76:950-956.

  18. Wikland M, Bergh C, Hillensjo T, Hoewles, et al. A prospective, randomized comparison of two starting doses of recombinant FSH in combination with cetrorelix in women undergoing ovarian stimulation for IVF/ICSI. Human Reproduction 2001;16:1676-1681.

  19. Out H, Rutherford A, Fleming R, Tayet C, et al. A randomized, double-blind, multicenter clinical trial comparing starting doses of 150 and 200 IU of recombinant FSH in women treated with the GnRH antagonist ganirelix for assisted reproduction. Human Reproduction 2004;19:90- 95.

  20. Jayaprakasan K, Hopkisson J, Campbell B, Johnson I, et al. A randomized controlled trial of 300 versus 225 IU recombinant FSH for ovarian stimulation in predicted normal responders by antral follicle count. International Journal of Obstetrics and Gynaecology 2010;853-852.

  21. Rombauts L. Is there a recommended maximum starting dose of FSH in IVF? J Assist Reprod Genet 2007;24:343- 349.




2020     |     www.medigraphic.com